Merck Develops 'New And Improved' CRISPR
Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.
You may also be interested in...
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.